- Pin
- 🏆 Gate Wins “Best Crypto Exchange 2025”!
Gate has been awarded Best Crypto Exchange 2025 at the E-Business Awards by Entrepreneur Middle East, recognizing Gate’s achievements in security, compliance, and user trust.
Thank you to our global community — we’ll keep building a safer, more reliable crypto experience!
- Growth Points Round 1️⃣ 1️⃣ Summer Lucky Grand Draw is on fire!
Draw now for your chance to win an iPhone 16 Pro Max and exclusive merch!
👉 https://www.gate.com/activities/pointprize?now_period=11
🎁 100% win rate! Complete simple tasks like posting, liking, commenting in Gate Post to enter the draw.
iPhone 16 Pro Max 512G, Gate hoodies, Sportswear, popular tokens, Futures Vouchers await you!
Collect just 2 fragments to easily redeem Gate merch—take your rewards home!
Ends on June 4th, 16:00 UTC. Try your luck now!
More info: https://www.gate.com/announcements/article/45185
- Earning Growth Points can win an iPhone 16?
Gate Post Growth Points Summer Lucky Draw Round 1️⃣ 1️⃣ Is Live!
🎁Prize pool over $10,000! Win iPhone 16 Pro Max 512G, exclusive Gate merch, popular tokens & more!
Try your luck now 👉 https://www.gate.com/activities/pointprize?now_period=11
How to earn Growth Points fast?
1️⃣ Go to [Post], tap the icon next to your avatar to enter [Community Center]
2️⃣ Complete daily tasks like posting, commenting, liking, and chatting to earn points
New feature this round: “Fragment Exchange”! Collect fragments to redeem exclusive Gate merch!
100% chance to win
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company's innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.